Edition:
United States

bluebird bio Inc (BLUE.O)

BLUE.O on Nasdaq

213.35USD
16 Feb 2018
Change (% chg)

$4.70 (+2.25%)
Prev Close
$208.65
Open
$206.05
Day's High
$213.70
Day's Low
$205.37
Volume
645,814
Avg. Vol
911,740
52-wk High
$222.03
52-wk Low
$73.95

Chart for

About

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $10,460.19
Shares Outstanding(Mil.): 49.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority

* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY

Jan 25 2018

Bluebird to seek approvals for three treatments by end of 2019

U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

Jan 09 2018

CORRECTED-Bluebird to seek approvals for three treatments by end of 2019

Jan 9 U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

Jan 09 2018

BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019

* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019

Jan 09 2018

BRIEF-Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors

* MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS Source text - http://bit.ly/2DfAvDy Further company coverage: (Gdynia Newsroom)

Dec 20 2017

BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share

* BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 12 2017

BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

* BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Dec 11 2017

BRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration

* BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY

Dec 07 2017

BRIEF-Bluebird Bio Acquires Manufacturing Facility In North Carolina

* BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Bluebird Bio says to receive $15 mln option exercise payment from Celgene​

* Bluebird Bio Inc - to receive $15 million option exercise payment from Celgene​

Sep 28 2017

Earnings vs. Estimates